Abstract
F15063 (N-[(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)ethyl]-3-(cyclopent-1-enyl)-benzylamine fumarate salt) is a novel potential antipsychotic with dopamine D2/D3 blocking properties and agonist activity at 5-HT1A and D4 receptors. The pertinent parameter for pharmacological activity of antipsychotics appears to be central D2-like receptor occupancy. However, its duration is not necessarily correlated with drug plasma levels, on which clinical dosing regimens are often based. Thus, we compared in mice the duration of actions of F15063 and haloperidol to (1) inhibit apomorphine-induced climbing and sniffing (behavioural measures of D2-like receptor antagonism) and (2) occupy D2-like receptors in vivo in the striatum and olfactory tubercles (inhibition of [3H]nemonapride binding). Finally, we measured plasma levels of F15063. D2-like receptor occupancy in the striatum remained elevated at 1, 4 and 8 h postadministration, with both F15063 (ID50: 7.1, 3.6 and 16.5 mg/kg p.o., respectively) and the typical antipsychotic, haloperidol (ID50: 1.4, 0.52 and 0.53 mg/kg p.o., respectively). This was paralleled by a protracted inhibition of apomorphine-induced climbing (ED50: 0.9, 2.8 and 3.6 mg/kg p.o., and 0.21, 0.37 and 0.87 mg/kg p.o., respectively, for F15063 and haloperidol). In contrast, after administration of 10 mg/kg p.o. of F15063, its plasma levels decreased rapidly: 15.2, 2.1 and 0.6 ng/ml, 1, 4 and 8 h after administration, respectively. A similar pattern of results was observed when F15063 and haloperidol were administered i.p. and s.c., respectively. To summarise, the time-course of D2-like receptor occupancy and inhibition of apomorphine-climbing (and sniffing) behaviours was similarly long lasting with F15063 and haloperidol. In addition, the durations of action of F15063 and haloperidol in a behavioural model of antipsychotic-like activity were closely correlated to their occupancy of central D2-like receptors, and much longer than their presence in plasma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abi-Dargham A, Laruelle M (2005) Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 20:15–27
Arnt J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63–101
Assié M-B, Bardin L, Auclair A, Consul-Denjean N, Sautel F, Kleven MS, Depoortère R, Newman-Tancredi A (2006a) F15063, a novel antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: III) Duration of brain D2-like receptor occupancy, antipsychotic-like activity and plasma concentration in rodents. Eur Neuropsychopharmacol 16(Suppl 4):S432
Assié M-B, Dominguez H, Consul-Denjean N, Newman-Tancredi A (2006b) In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles. Naunyn Schmiedebergs Arch Pharmacol 373:441–450
Bantick RA, Deakin JFW, Grasby PM (2001) The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 15:37–46
Bardin L, Kleven MS, Barret-Grevoz C, Depoortère R, Newman-Tancredi A (2006) Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. Neuropsychopharmacology 31:1869–1879
Bressan RA, Erlandsson K, Jones HM, Mulligan R, Flanagan RJ, Ell PJ, Pilowsky LS (2003) Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect?-An in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. Am J Psychiatry 160:1413–1420
Cuisiat S, Bourdiol N, Lacharme V, Newman-Tancredi A, Colpaert FC, Vacher B (2007) Towards a new generation of potential anti-psychotic agents combining D2 and 5-HT1A receptor activities. J Med Chem 50:865–876
Depoortère R, Auclair A, Bardin L, Bruins Slot LA, Kleven MS, Colpaert FC, Vacher B, Newman-Tancredi A (2007a) F15063, a compound with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (III) Profile in tests predictive of activity against cognitive deficits and negative symptoms of schizophrenia. Br J Pharmacol. DOI 10.1038/sj.bjp.0707160
Depoortère R, Bardin L, Auclair A, Kleven MS, Prinssen EPM, Colpaert FC, Vacher B, Newman-Tancredi A (2007b) F15063, a compound with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (II) Profile in tests predictive of activity against positive symptoms of schizophrenia. Br J Pharmacol. DOI 10.1038/sj.bjp.0707159
Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 dopamine and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine- relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538–544
Hertel P, Brennum LT, Helboe L, Olsen CK, Kreilgaard M, Marquis K, Svensson TH, Herremans AHJ, Hesselink M (2005) Bifeprunox: relationship between antipsychotic potential, EPS liability and dopamine D2 receptor occupancy in rats. Neuropsychopharmacology 30(Suppl 1s):S256
Hirose G (2006) Drug induced parkinsonism: a review. J Neurol 253(Suppl 3):III/22–III/24
Kapur S, Mamo D (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharm Biol Psychiatry 27:1081–1090
Kapur S, Remington G (2001) Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 50:873–883
Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000) Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514–520
Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN (2003) Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305:625–631
Lee BH, Kim YK (2006) The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Prog Neuropsychopharm Biol Psychiatry 30:658–662
Leucht S, Wahlbeck K, Hamann J, Kissling W (2003) New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361:1581–1589
Maguire GA (2002) Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 63(Suppl 4):56–62
Medori R, Mannaert E, Grunder G (2006) Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. Eur Neuropsychopharmacol 16:233–240
Millan MJ (2000) Improving the treatment of schizophrenia: focus on serotonin (5-HT)1A receptors. J Pharmacol Exp Ther 295:853–861
Moghaddam B, Bunney BS (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54:1755–1760
Newman-Tancredi A, Assié M-B, Martel JC, Cosi C, Bruins Slot LA, Palmier C, Rauly-Lestienne I, Colpaert FC, Vacher B, Cussac D (2007) F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (I) in vitro, receptor affinity and efficacy profile. Br J Pharmacol. DOI 10.1038/sj.bjp.0707158
Olsen CK, Brennum LT, Kreilgaard M (2006) Pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. Society for Neuroscience, Atlanta, GA, 2006 Online 93.15
Protais P, Costentin J, Schwartz JC (1976) Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacology 50:1–6
Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27–38
Sharma RP, Shapiro LE (1996) The 5-HT1A receptor system: possible implications for schizophrenic negative symptomatology. Psychiatr Ann 26:88–92
Stephenson CM, Bigliani V, Jones HM, Mulligan RS, Acton PD, Visvikis D, Ell PJ, Kerwin RW, Pilowsky LS (2000) Striatal and extra-striatal D2/D3 dopamine receptor occupancy by quetiapine in vivo. [123I]-epidepride single photon emission tomography (SPET) study. Br J Psychiatry 177:408–415
Takano A, Suhara T, Ikoma Y, Yasuno F, Maeda J, Ichimiya T, Sudo Y, Inoue M, Okubo Y (2004) Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. Int J Neuropsychopharmacol 7:19–26
Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S (2002) Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 7:317–321
Tort ABL, Souza DO, Lara DR (2006) Theoretical insights into the mechanism of action of atypical antipsychotics. Prog Neuropsychopharm Biol Psychiatry 30:541–548
Vacher B, Cuisiat S, Koek W, Colpaert FC (2002) 3-(Cyclopenten-1-yl)-benzyl-or 3-(Cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia. Patent n° WO 2004/035561 A1. Priority 16 October 2002
Wolf W (2003) DU-127090. Curr Opin Investig Drugs 4:72–76
Zetler G, Baumann GH (1985) Pharmacokinetics and effects of haloperidol in the isolated mouse. Pharmacology 31:318–327
Acknowledgements
We thank Martine Barreto, Catherine Barret-Grevoz, Joël Besnard, Elodie Bernard and Lydia Hejoaka for their excellent technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Assié, MB., Bardin, L., Auclair, A. et al. F15063, a potential antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice. Naunyn-Schmied Arch Pharmacol 375, 241–250 (2007). https://doi.org/10.1007/s00210-007-0162-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-007-0162-x